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Abstract
Foot-and-Mouth Disease (FMD), as a major global animal disease, affects millions of animals worldwide and
remains the main sanitary barrier to the international and national trade of animals and animal products.
Inactivated vaccination is the most effective measure for prevention of FMD at present, but fail to induce long-
term protection and content new requires for production of FMD vaccines. As a number of Researchers hope to
obtain satisfactory novel vaccines by new bio-technology, novel vaccines have been studied for more than thirty
years. Here reviews the latest research progress of new vaccines, summarizes some importance and raises several
suggestions for the future of FMD vaccine.
1 Introduction
Foot-and-mouth disease (FMD) is a severe, highly con-
tagious and economically devastating viral disease
worldwide (Table 1), which affects animals with cloven
hoofed animals, such as cattle, pigs, deer, goats and
sheep. It has been reported many outbreaks around the
world since FMD firstly broke out in America in 1870.
Although not usually fatal, FMD, as a renewed public
and political high-profile disease, has aroused the global
concerns [1,2]. It not only reduces animals’ commercial
value by decreasing animals’ weight and milk output,
but is also the most important animal disease limiting
commerce of animals and animal products [3]. For
those reasons, it is significant to prevent, control and
even eradicate FMD.
Vaccines, available since the early 1900s, have been
the most instrumental method for prevention and con-
trol of FMD. Nowadays, FMD vaccine is produced by
growing live velogenic foot-and-mouth disease virus
(FMDV) in BHK-21 cell cultures under bio-secure con-
ditions and inactivating it by using a chemical such as
binary ethyleneimine. However, the mode of production
exist a risk to reveal live FMDV to environment. The
risk should be considered by government when FMD
has been effectively controlled. Moreover, at the begin-
ning of the 21st century, the protocol for production of
inactivated FMD vaccines allows the use of serological
tests that can differentiate infected from vaccinated ani-
mals, formulation of vaccines that include multiple sero-
types and subtypes and a number of adjuvants [4].
Besides, there are other important shortcomings of cur-
rent inactivated vaccines, including short shelf life, the
need for adequate cold chain of formulated vaccines,
and difficulties of certain serotypes and subtypes to
grow well in cell culture for vaccine production [5]. In
addition, a risk from epidemic areas still exists in coun-
tries and areas having been free of FMDV. In order to
address these problems, new vaccines are necessary and
urgent to develop into satisfied candidates of classical
vaccines. According to mechanism, form and source of
vaccine, this article reviewed the latest research progress
of novel vaccines and some viewpoints for the develop-
ment of FMD vaccines.
2 subunit vaccine
Subunit vaccine is a vaccine containing viral antigens
made free of viral nucleic acid by chemical extraction or
bio-expressing and containing only minimal amounts of
non-viral antigens derived from the culture medium. It
is less likely to cause adverse reactions than a vaccine
containing the whole virion.
With the development of information concerning viral
capsid structure, researchers had determined that VP1,
one of the FMDV capsid proteins, had a prominent sur-
face exposure in 1970s [6,7]. Based on this information
and related researches, a number of strategies were
designed to develop subunit vaccines as alternatives to
conventional inactivated vaccine. In 1975, Bachrach et
al. firstly obtained VP1 isolated from purified viruses
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In 1981, Kupper cloned the VP1 gene, transferred it
into E.coli in the form of recombinant plasmid and har-
vested the VP1 [9]. Results indicated that VP1 produced
in E. coli could protect both swine and cattle from virus
challenge [10]. Wang JH, et al. refolded the VP1 with
t h ea s s i s t a n to fS D Sa n do b t a i n e dp u r i f i e dV P 1a n d
induced neutralizing antibody responses to every refold-
ing VP1. There was a protective immune response
against FMDV challenge in guinea pigs vaccinated with
recombinant P1 polyprotein expressed in Pichia pastoris
[11]. Shi et al. verified fusion protein of bovine IFN-
ga n dF M D VV P 1a n t i g e ne x p r e s s e di nP .p a s t o r i sc o u l d
induce an immune response to FMDV antigens [12].
To study FMDV structural proteins and non-structure
proteins (NSP), researchers screened several epitopes of
VP1. Luis et al. found that TrpE fusion proteins contain-
ing portions of the C -terminal region of FMDV VP1
can induce a neutralizing antibody response and certain
protection in animal test [13]. Subsequently, Yang and
Zhuang separately tested the immune effect of fusion
proteins including T cell and B cell epitopes. The results
indicated that fusion proteins could cause humoral and
cellular immune response [14,15].
Empty viral capsids are virus particles lacking nucleic
acid which are naturally produced in infected cells and
are as immunogenic as virions [7]. In 1979, Rweyemamu
confirmed stability and immunogenicity of empty parti-
cles of FMDV. Subsequent studies reviewed in vitro
expresstion of P1-2A and 3C in cells reformed 76s
virus-like particles [16]. And Li et al. screened MDBK
cells stably co-expressing the capsid precursor protein
P 1 - 2 Ag e n ea n dt h ep r o t e a s e3 Cg e n eo fF M D V[ 1 7 ] .
The immune effective of virus-like particles is similar to
whole FMDV.
Recently new subunit vaccines for FMDV were fre-
quently reported, however, there were no subunit vac-
cines revealing advanced effective compared with
traditional inactivated vaccines. In spite of it, subunit
vaccines are still widely regarded as optimal candidates
instead of classical inactivated vaccines for advantages,
such as high security and the use of serological tests
that can differentiate infected from vaccinated animals
[4,18]. This ideal can be most likely achieved by the
development of empty capsid vaccines in future. Utiliz-
ing the baculovirus-silkworm expression system, Li et al.
developed recombinant virus vaccine, the immunological
assays of guinea pigs demonstrated that this vaccine
showed good immunogenicity and long immune
persistence.
During the analysis and test of them, some subunit
vaccines induced limited protection against virus.
According to the characterization of various target pro-
tein, it is necessary for subunit vaccines to select an
appropriate expression system, such as Bacillus subtilis
[19], Cyanobacteria [20], Filamentous fungus [21],
Escherichia coli [9], Pichia pastoris [22], Baculovirus
[23], Mammalian cell and so on. The last four expres-
sion systems of them have been utilized to the develop-
ment of FMD vaccines. As FMDV is further detailed
and expression systems are optimized and improved, the
development of subunit vaccines will be promoted.
3 live vector vaccine
A live vector vaccine is a vaccine that uses a chemically
weakened virus to transport pieces of the virus to stimu-
late an immune response. Adenovirus [24] and poxvirus
are widely utilized to efficiently express heterologous
genes.
The structure and function of Adenovirus genome has
been studied thoroughly. Searchers exploited replica-
tion-defective adenovirus serotype 5 (Ad5) as live vector
carrying 5 kb~8 kb DNA fragment. Juilliard et al. veri-
fied that a single immunization with a replication-defec-
tive adenovirus recombinant vector induces long-lasting
humoral and cellular immune responses specific to the
transgenic product [25,26]. Sanz-Parra cloned FMDV P1
gene into Ad5 genome. The animal test displayed that
recombinant viruses induced cellular but not humoral
antiviral immunity and partial protection in pigs [27].
Mayr developed replication-defective Ad5 containing the
capsid and 3C protease coding regions of foot-and-
mouth disease virus as a vaccine candidate [28]. The
replication-defective Ad5, encoding the FMDV capsid
Table 1 Various serotypes in FMDV distribution areas
Area Main serotypes in FMDV distribution areas
Type O Type A Type C Type Asia I SAT-1 SAT-2 SAT-3
China + + - + - - -
Southeast Asia + + - + - - -
Africa + - - - + + +
Middle East + + + + - - -
United Kingdom + - - - - - -
South America + + + - - - -
“+” means positive, and “-” means negative.
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induced generated high levels of FMDV-neutralizing
antibodies 4 weeks later resulting in complete protection
of five of the six swine and limited disease in the
remaining animal [28]. Early protection against homolo-
gous challenge was provided to swine inoculated replica-
tion-defective Ad5 expressing capsid proteins of FMDV
strain A24 [29]. Correlational researches adenovirus-vec-
tored FMDV vaccine also aroused a rapid protection of
cattle from direct challenge with FMDV [30]. Recently
studies indicated that there was effective protection of
guinea pigs and swine by a recombinant adenovirus
expressing O serotype of foot-and-mouth disease virus
whole capsid and 3C protease [31].
Some researchers had an attempt to exploit recombi-
nant vaccinia virus [32] fowlpox virus [33] and pseu-
dorabies virus [34] expressing FMDV structural protein,
non-structure protein or both of them, but swine and
guinea pigs inoculated with multiple doses were partially
protected because of their low level of expression. How-
ever, FMD vaccines are required to protect animals
from FMDV challenge by a single dose of vaccine in the
epidemic period. Although the live vector vaccines
appear promising, they are still at earlier stages of test-
i n ga n dd e v e l o p m e n tc o m p a r e dt ot h es u b u n i tv a c c i n e
candidates.
4 Nucleic acid vaccines
Nucleic acid vaccines are genetically engineered DNA to
produce an immunological response in injected animals.
It has been applied to a number of viral, bacterial and
parasitic disease models as well as several tumour mod-
els. There are a number of advantages on nucleic acid
vaccines over conventional vaccines, such as long-term
protection, long shelf life [35] and the ability to induce a
wider range of immune response types.
Plasmids have been used for development of DNA
vaccines as ideal materials. Plasmids encoding FMDV
structural protein and non-structural protein elicited
immune responses in mice and swine and protected
swine against viral infection [36]. Same other
researches reviewed same results [37]. One of the hot-
spots of new studies of DNA vaccine is focus on the
influence of cytokine. Multiple cytokine has been
tested as adjuvants of DNA vaccines. There is Table 2
showing the influence of various cytokine on FMDV
DNA vaccine [12,38-44]. Based on a large number of
tests, some cytokines were identified as effective adju-
vants of DNA vaccines. In further researches and
development of DNA vaccines, cytokines will play a
key role.
5 Novel attenuated vaccine
Novel attenuated vaccines are engineered to knock out
some regions or oligonucleotides of viruses by biotech-
nology but not continuously cultured in a non-native
susceptible host just as traditional attenuated vaccines.
Compared with classical attenuated vaccines, new atte-
nuated methods are stable and low risk of toxicity rever-
sion. There are mainly two strategies exploited to
develop novel attenuated vaccines. Based on the
researches of FMDV receptor, receptor binding site-
deleted (or replaced) FMDV attenuated vaccine has
been explored to protect cattle from FMD [45,46]. On
the basis of experimental researches into non-required
for viral replication, live-attenuated vaccines prepared
from a leader proteinase-deficient serotype A12 FMDV
[47-49] provided an effective protection to cattle from
the challenge of FMDV. These series of experiments
demonstrate the potential of a rationally designed live-
attenuated FMDV vaccine.
With deeply fundamental researches on the structure
and functionality of FMDV proteins, rising mechanisms
of virulence and pathogenicity have been reviewed. The
leader proteinase of FMDV inhibits the induction of
beta interferon mRNA and blocks the host innate
immune response [50]. But little is known about other
virulence determinants among FMDV genome. As new
virulence determinants are identified, the artificial atte-
nuated vaccines will have a further development on
Table 2 The influence of various cytokine on FMDV DNA vaccine
Cytokine Effective on FMDV DNA vaccine
IL-1/IL-2 Advanced the humoral immune response induced by FMD inactivated vaccines. [38,39]
IL-6 Advanced the cellular immune response induced by FMD DNA vaccines, Promoting the maturation and immune function of dendritic
cells [40]
IL-9 Increased a robust antigen specific cytotoxicity T lymphocyte response [41]
IL-15 Enhanced the cellular and mucosal immune response and the level of IFN-ginduced by FMD DNA vaccines [42]
IL-18 Increased the immunogenicity of DNA vaccines coding P12A and 3C of FMDV [43]
CSF Enhanced immune responses against a plasmid DNA vaccine encoding FMDV empty capid [44]
INF-a/b Advanced the cellular immune response induced by FMD DNA vaccines, Promoted the maturation and immune function of dendritic
cells
INF-g Enhanced both humoral and cell-mediated immune responses[12]
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reversion to virulence is established.
6 Synthetic peptide vaccine
Synthetic peptide vaccine is a viral peptide synthesized
by chemical approaches, including antigen epitopes.
With the development of information concerning
FMDV antigen determinants, antigen regions repre-
sented the variable G-H loop found on the surface of
the FMDV capsid [51,52] and the carboxy-terminal
region of VP1 and corresponded to B cell epitopes. In
an earlier experiments [53-55], peptide vaccines against
a single epitope of FMD just indicated the limited
immunogenicity and particle protection. Further
researches implied that an effectively protective VP1
peptide vaccine needs the addition of promiscuous Th
sites from a source outside VP1 [56-58] and potent B
cell sites for the induction of high affinity neutralising
antibodies [59,60]. On the basis of the above researches,
researchers have designed novel synthetic peptide vac-
cines with T and B cell sites optimised for both immu-
nogenicity and antigenic cross-reactivities. This peptide
immunogen spans the entire G-H loop domain and
extensive flanking sequences (129-169), has a unique
consensus sequence to confront the hypervariability of
serotype O viruses, and includes a promiscuous artificial
Th site [61]. A dendrimeric peptide vaccine was
described to protect pigs against challenge with FMDV
and induce high titers of FMDV neutralizing antibodies,
activated FMDV-specific T cells and a potent anti-
FMDV immunoglobulin A response [62]. The research
suggested that peptide vaccines representing appropriate
advanced structure preferably more possibly induced a
fully protective immune response, and rational designs
of advanced structure of antigen peptide would provide
a new development of peptide vaccines.
Conclusion
The globalization of commerce is accelerating the
spread of FMDV and presents new requirements on the
trade of animals and animal productions. But novel vac-
cines against FMDV are developed slowly, and only few
available novel FMD vaccines have been used in prac-
tice. New vaccines are still just tested and evaluated in
laboratory and clinic, due to limited details on immune
mechanism of each of novel vaccines and the basic
researches of FMDV. However, a number of results
implied that there were observed advantages and disad-
vantages on novel vaccines arrange the security of pro-
duction, the security of vaccinated animal, shelf life,
duration of immune response, vaccination effectiveness
and differentiation of infected animals from vaccinated
ones(Table 3).
We should also do some efforts to the development of
adjuvants and immunization strategies. Some research-
ers reported that combination immunization with DNA
vaccines and subunit vaccines or synthetic peptide vac-
cines could induced a high-titer specific antibodies and
cellular immunity. This strategy will be a nearest way to
make different vaccines complement each other and
proceed to the practice of novel vaccines, on the condi-
tion that researchers are puzzled to develop a single
novel vaccine for controlling FMDV.
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Table 3 Advantages and disadvantages of different novel vaccines
Novel vaccines security of
production
security of vaccinated
animal
shelf
life
duration of
immune response
vaccination
effectiveness
Differentiation of infected animals
from vaccinated ones
Subunit vaccine Yes Yes Normal Normal Low Yes
Live vector
vaccine
Yes Yes Normal Long High Yes
Nucleic acid
vaccine
Yes Risk to recombinant to
other genomes
Long Long Low Yes
Novel
attenuated
vaccine
Yes Risk to toxicity reversion
but low
Normal Long High Yes
Synthetic
peptide vaccine
Yes Yes Normal Short Low Yes
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